VANCOUVER, British Columbia, April 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it will be attending the Tennessee Safety and Health Conference (TSHC) in Nashville, TN commencing on April 7th. Cannabix will attend the conference with AlcoPro Inc. to exhibit the Company’s laboratory-based Marijuana Breath Test (MBT) and BreathLogix autonomous (unmanned) alcohol screening device (See Figures 1-3). The TSHC supported by the Tennessee Occupational Safety and Health Administration (TOSHA) and offers a variety of workplace safety and health education sessions geared toward managers as well as front-line workers and will be attended by corporations and professionals in the drug and alcohol testing industry.
Figure 1. Cannabix Breath Collection Unit and Breath Cartridge technology (collect and send solution)
Figure 1. Cannabix Breath Collection Unit and Breath Cartridge technology (collect and send solution)
Highlights:
Cannabix and AlcoPro Inc. will attend TSHC in Nashville, TN. AlcoPro (of Knoxville, TN) is collaborating with Cannabix to begin marketing the MBT and BreathLogix technologies. AlcoPro is a well-established distributor and leading supplier of drug and alcohol testing instruments and supplies in the United States.
Cannabix’s MBT is a collect and send solution (portable sample breath collection, tested via laboratory analysis) focused on “recent use” detection of delta-9 THC. Unlike urine, blood and saliva methods, that can detect delta-9 THC for many hours, days, or even weeks after consumption, the Cannabix MBT provides a more relevant THC consumption window (1). Omega Laboratories announced development and validation of the Cannabix MBT in March 2025. The validation included a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols using the Cannabix Breath Collection Unit (BCU) and Breath Cartridge (BC).
The BreathLogix series are unmanned wall mounted alcohol screening devices for a range of employment and test settings where alcohol safety and monitoring are required.
BreathLogix Alcohol Screening Devices
The Company’s BreathLogix unmanned alcohol screening devices hosts several features including patent pending pre-calibrated cartridge technology which will allow administrators to easily maintain their devices, and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance. The devices can be used for pre-access alcohol testing, random testing, start-of-shift testing, pre-employment testing, return-to-work testing and post-incident testing.
BreathLogix autonomously checks the sobriety of a user and can take a picture to confirm and record identity while a breath sample is being delivered. Upon detection of positive breath alcohol result, the device will deliver a precise Blood Alcohol Content (BAC) level on the screen, and send a real-time test report via text message, e-mail and to a dedicated web portal. Furthermore, the system logs user test reports for incident reporting and historical investigations.
Figure 2. BreathLogix Alcohol Screening Devices
Figure 2. BreathLogix Alcohol Screening Devices
BreathLogix WS action photo
Figure 3. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening
Change of Auditor:
The Company reports that it has changed its auditor from Saturna Group Chartered Professional Accountants LLP (“Former Auditor”) to SHIM and Associates LLP, (“Successor Auditor”) effective April 4, 2025.
The Companys' board of directors accepted the resignation of the Former Auditor, as of April 4, 2025 and appointed the Successor Auditor as the new auditor of the Company effective April 4, 2025, and to hold office until the close of the Company's next annual general meeting of shareholders.
There were no reservations in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor. There are no "reportable events" (as the term is defined in National Instrument 51-102 - Continuous Disclosure Obligations) between the Company and the Former Auditor. In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Company's audit committee and board of directors and will be filed on SEDAR accordingly.
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. 2017. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Testing and Analysis, 9(6), 905–915.
Musshoff F & Madea B. 2006. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 28(2),155-63.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. The Marijuana Breath Test (also referred to as the “MBT” or Cannabix Marijuana Breathalyzer “CMB”) is a laboratory based test that relies on portable breath collection and capture technology developed by the Company and analysis is completed using laboratory mass spectrometry; Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by domestic or international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories and or partnerships, MOUs with third-parties; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop, manufacture, market and sell its products; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the Company’s development of breath testing technologies will provide any benefit to the Company; there is no assurance that any proposed new or existing products will be built, will be successful in beta, trial, pilot testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breath testing devices and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at:
